- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01848886
Neurological Complications Comparing Endoscopically vs. Open Harvest of the Radial Artery (NEO)
Endoscopic Versus Open Radial Artery Harvest and Mammario-radial Versus Aorto-radial Grafting in Patients Undergoing Coronary Artery Bypass Surgery (The 2x2 Factorial Designed Randomised NEO Trial)
Study Overview
Status
Conditions
Detailed Description
Objectives
The present trial will in patients undergoing CABG (1) evaluate the complications in endoscopic versus traditionally harvested radial arteries, (2) evaluate graft patency in endoscopic harvested radial arteries versus open technique, and (3) evaluate the use of mammario-radial grafting versus aorto-radial grafting.
Design and trial size
The NEO Trial is a randomised clinical trial with a 2x2 factorial design. We plan to randomise 300 participants into four intervention groups: (1) mammario-radial endovascular group; (2) aorto-radial endovascular group; (3) mammario-radial open group and (4) aorto-radial open group. A subgroup of 100 participants will be selected to undergo a special scanning of the vascular perfusion of donor and control hands (MIBI scan). The evaluation of graft patency and ischaemia in the arm will be blinded but the assessment of the primary outcome of handfunction at three months is non-blinded evaluated by questionnaire.
Trial interventions
Trial 1: The experimental procedure in this trial will be endoscopic radial artery harvest (ERAH). The control intervention will be open radial artery harvest (ORAH).
Trial 2: The experimental procedure in this trial will be the technique where the radial artery is sewn onto the mammarian artery as a mammario-radial anastomosis (composite/Y-graft). The control intervention will be the technique of sewing the radial artery directly onto the aorta as an aorto-radial anastomosis (free radial artery).
Inclusion and exclusion criteria
All patients referred to our department for sub acute or elective coronary bypass operation will be eligible for trial inclusion. Inclusion criteria are: 18 years or older; able and willing to give informed consent; multi-vessel disease. Exclusion criteria are: off-pump procedure; multi-procedure (i.e. concomitant valve surgery); contrast allergy; geographically not available for follow-up; Allen's test with insufficient ulnary artery perfusion; no informed consent; acute operation; dialysis; preoperative neurological deficit on the donor arm; left ventricle ejection fraction (LVEF) less than 20%; former sternotomy and malignant disease.
Primary and secondary outcomes
Trial 1: The primary outcome will be evaluation of hand function at three months.
The secondary outcomes will be: occurrence of neurophysiological defects in the donor arm assessed by examination of cutaneous sensibility and measurements of the sensory and motoric nervous conduction velocity preoperatively and after three months; change in subjective cutaneous sensibility assessed by a clinical examination after three months; complications assessed as a composite of haematoma formation, wound dehiscence or infection registered before discharge and after three months.
We will also assess a number of exploratory outcomes (serious adverse events, reoperation for bleeding, revascularisation, myocardial infarction, stroke or death, handgrip strength, muscular function in the hand, scar evaluation, vascular supply to the hand, graft patency and participants subjective evaluation of hand function after 1 year).
Trial 2: The primary outcome will be the occurrence of cardio- or cerebrovascular events during the first year after surgery comparing mammario-radial versus aorto-radial grafts. As an exploratory outcome we will also assess graft patency by multi-slice computer tomography (MSCT) comparing mammarioradial versus aortoradial grafts one year after surgery.
Time schedule
Randomisation will commence after 15th of May 2013. The inclusion period of altogether 300 participants is expected to last three years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Elective/sub acute CABG as an isolated procedure.
- Age > 18 years
- Multi-vessel disease
- Non-dominant arm is eligible for radial artery harvest
- Written informed consent
Exclusion Criteria
- Geographically not available for follow up
- Modified Allen's test indicating insufficient ulnary artery perfusion
- Valve surgery, ablation surgery or any kind of concomitant surgery during same admission.
- Acute operation (<24 hours from admission)
- Dialysis
- Preoperative neurological deficit on the donor arm
- LVEF < 20% preoperative
- Former sternotomy
- Contrast allergy
- Malignant disease
- No written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Grp 1: ERAH, Mammarioradial (Y-graft)
Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
|
Radial artery harvest is performed as an endoscopic procedure.
The radial artery is used as an composite graft positioned on the internal mammarian artery.
|
|
Other: Grp 2: ERAH, Aortoradial (Free RA)
Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
|
Radial artery harvest is performed as an endoscopic procedure.
The radial artery is used as an free graft positioned on the aorta.
|
|
Other: Grp 3: ORAH, Mammarioradial (Y-graft)
Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
|
The radial artery is used as an composite graft positioned on the internal mammarian artery.
Radial artery harvest is performed as an open procedure.
|
|
Other: Grp 4: ORAH, Aortoradial graft (Free RA)
Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
|
The radial artery is used as an free graft positioned on the aorta.
Radial artery harvest is performed as an open procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sum score of hand function questionnaire
Time Frame: 3 months postoperatively
|
Using Likert-type scale scoring system quality of life is assessed after radial artery harvest.
The mean values in the ERAH group will be compared to the mean value in the ORAH group at three months after surgery.
|
3 months postoperatively
|
|
Occurence of cardiac and cerebrovascular events in aortoradial versus mammarioradial grafting
Time Frame: 1 year postoperatively
|
Occurrence of one of the following cardiac or cerebrovascular events: all cause mortality, myocardial infarction (MI), target vessel revascularisation (TVR) or stroke at one year postoperatively will be compared.
|
1 year postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complications in the donor arm in ERAH versus ORAH
Time Frame: 3 months postoperatively
|
Occurrence of complications at three months after surgery.
Complications are defined as a composite of haematoma formation, wound dehiscence, or infection will be compared.
|
3 months postoperatively
|
|
Clinical neurological examination in donor arm ERAH versus ORAH
Time Frame: 3 months postoperatively
|
Clinical examination of subjective cutaneous sensibility will be compared between ERAH versus ORAH groups.
|
3 months postoperatively
|
|
Neurological deficits in ERAH versus ORAH
Time Frame: 3 months postoperatively
|
Occurence of deficits in following neurological exams will be compared between ERAH and ORAH
|
3 months postoperatively
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vascular function in the donor arm of the ERAH and ORAH groups compared to non-donor arms.
Time Frame: 3 months postoperatively
|
MIBI scan after exercise induced relative ischemia will be compared between donor versus non-donor arms.
|
3 months postoperatively
|
|
Graft patency in ERAH versus ORAH
Time Frame: 1 year postoperatively
|
MSCT will be used to evaluate patency.
|
1 year postoperatively
|
|
Graft patency in aortoradial versus mammarioradial grafting
Time Frame: 1 year postoperatively
|
MSCT will be used to evaluate patency.
|
1 year postoperatively
|
|
Change in handgrip strength
Time Frame: the day before surgery and 1 year postoperatively.
|
Change in handgrip strength will be measured in the conduit donor arm and compared between ERAH versus ORAH.
|
the day before surgery and 1 year postoperatively.
|
|
Change in muscular function in ERAH versus ORAH
Time Frame: the day before surgery and 1 year postoperatively
|
Following muscles are rated according to the Oxford Scale for grading muscle strength (see table 7) the day before surgery and at one year postoperatively:
|
the day before surgery and 1 year postoperatively
|
|
Serious adverse events in ERAH versus ORAH
Time Frame: 1 year postoperatively
|
Occurrence of the following serious adverse events at time point one year after surgery: reoperation for bleeding; revascularisation; myocardial infarction; stroke; or death will be compared between ERAH and ORAH.
|
1 year postoperatively
|
|
Scar evaluation in ERAH versus ORAH
Time Frame: 1 year postoperatively
|
Using Stony Brooke Scar Evaluation Score the scars will be evaluated and the mean scores compared between ERAH versus ORAH groups.
|
1 year postoperatively
|
|
Neuropathic pain symptoms and signs in ERAH versus ORAH
Time Frame: 3 months postoperatively
|
The Leeds assessment of neuropathic symptoms and signs (LANNS) pain scale will be used after 3 months to compare pain in ERAH versus ORAH groups.
|
3 months postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christian L Carranza, MD, Department of Cardio-Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark
- Study Chair: Peter Skov Olsen, MD DMSc, Department of Cardio-Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark
- Study Chair: Christian Gluud, MD DMSc, Copenhagen Trial Unit, Rigshospitalet, Copenhagen, Denmark
- Study Chair: Martin Ballegaard, MD PhD, Department of Clinical Neurophysiology, Rigshospitalet, Copenhagen, Denmark
- Study Chair: Philip Hasbak, MD PhD, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
- Study Chair: Andreas Kjær, Prof MD DMSc, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
- Study Chair: Klaus F Kofoed, MD DMSc, Department of Cardiology and Radiology, Rigshospitalet, Copenhagen, Denmark
- Study Chair: Mads Werner, MD, DMSc, Multidisciplinary Pain Centre, Rigshospitalet, Copenhagen, Denmark
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-3-2012-116 (Other Identifier: Ethics Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
Shanghai Zhongshan HospitalRecruiting
-
Beijing Sungen Biomedical Technology Co., LtdRecruitingAnterior Myocardial InfarctionChina
-
Samsung Medical CenterThe Korean Society of CardiologyNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingMyocardial Infarction (MI)China
-
Rohan DharmakumarCompletedAcute Myocardial Infarction (AMI)India
-
Myomed Technology (Shaoxing) Co., Ltd.Not yet recruitingSTEMI - ST Elevation Myocardial InfarctionChina
-
Saglik Bilimleri UniversitesiOndokuz Mayis University Training and Research HospitalRecruitingST-elevation Myocardial Infarction (STEMI)Turkey (Türkiye)
-
Qian gengBeijing Chao Yang Hospital; Guizhou Provincial People's Hospital; Beijing Anzhen... and other collaboratorsNot yet recruitingST Elevation (STEMI) Myocardial InfarctionChina
-
Shenyang Northern HospitalRecruitingSTEMI - ST Elevation Myocardial InfarctionChina
Clinical Trials on Endoscopic radial artery harvest
-
Lawson Health Research InstituteJohnson & JohnsonCompletedCoronary Artery DiseaseCanada
-
Mansoura UniversityCompletedIschemic Heart Disease | Coronary Artery Bypass GraftEgypt
-
Sheba Medical CenterRecruitingCoronary Artery DiseaseIsrael
-
Wujin People's HospitalNot yet recruitingHand Functions | Coronary Arterial Disease (CAD) | Distal Raidal Artery
-
Saglik Bilimleri Universitesi Gazi Yasargil Training...CompletedCatheterization, PeripheralTurkey
-
Yale UniversityTerminatedSevere SepsisUnited States
-
Łukasz KozińskiCompletedCoronary Artery Disease | Vascular Access Complication | Coronary Angiography | Radial Artery | PuncturePoland
-
Tribhuvan University Teaching Hospital, Institute...Completed
-
Masarykova Nemocnice v Usti nad Labem, Krajska...Not yet recruitingEducational Problems | Catheterization | Simulation Based Medical Education | Education Nursing
-
University Hospital "Sestre Milosrdnice"UnknownVascular Diseases | Coronary Disease